Search research articles
Contact Us
Filters
Showing results (331-340 of 383) with videos related to
Page
of 39
Sort By:
British Journal of Cancer
|
April 11, 2019
Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial
Karin Ribi, Weixiu Luo, Marco Colleoni, et al.
Nature Communications
|
December 2, 2025
ctDNA detectability and representativeness in seven body liquids from patients with metastatic breast cancer
François Richard, Marion Maetens, Karen Van Baelen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 27, 2018
Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial
Thomas Ruhstaller, Anita Giobbie-Hurder, Marco Colleoni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 18, 2022
Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial
Francois-Clement Bidard, Virginia G Kaklamani, Patrick Neven, et al.
The Lancet. Oncology
|
November 22, 2017
Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial
Marco Colleoni, Weixiu Luo, Per Karlsson, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 16, 2022
Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant
Luca Malorni, Svitlana Tyekucheva, Florentine S Hilbers, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 21, 2020
Genomic Aberrations and Late Recurrence in Postmenopausal Women with Hormone Receptor-positive Early Breast Cancer: Results from the SOLE Trial
Elena Guerini-Rocco, Kathryn P Gray, Caterina Fumagalli, et al.
Breast (Edinburgh, Scotland)
|
June 17, 2026
De-escalated chemotherapy and endocrine therapy outcomes in young women with stage I HR+/HER2+ breast cancer: An international real-world study
Tal Sella, Frederieke van Duijnhoven, Hans Wildiers, et al.
Nature Communications
|
September 20, 2022
Single cell atlas identifies lipid-processing and immunomodulatory endothelial cells in healthy and malignant breast
Vincent Geldhof, Laura P M H de Rooij, Liliana Sokol, et al.
The New England Journal of Medicine
|
December 11, 2024
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer
Komal L Jhaveri, Patrick Neven, Monica Lis Casalnuovo, et al.
Page
of 39
Search research articles
Search
Showing results (331-340 of 383) with videos related to
Sort By:
Page
of 39
British Journal of Cancer
|
April 11, 2019
Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial
Karin Ribi, Weixiu Luo, Marco Colleoni, et al.
Nature Communications
|
December 2, 2025
ctDNA detectability and representativeness in seven body liquids from patients with metastatic breast cancer
François Richard, Marion Maetens, Karen Van Baelen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 27, 2018
Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial
Thomas Ruhstaller, Anita Giobbie-Hurder, Marco Colleoni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 18, 2022
Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial
Francois-Clement Bidard, Virginia G Kaklamani, Patrick Neven, et al.
The Lancet. Oncology
|
November 22, 2017
Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial
Marco Colleoni, Weixiu Luo, Per Karlsson, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 16, 2022
Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant
Luca Malorni, Svitlana Tyekucheva, Florentine S Hilbers, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 21, 2020
Genomic Aberrations and Late Recurrence in Postmenopausal Women with Hormone Receptor-positive Early Breast Cancer: Results from the SOLE Trial
Elena Guerini-Rocco, Kathryn P Gray, Caterina Fumagalli, et al.
Breast (Edinburgh, Scotland)
|
June 17, 2026
De-escalated chemotherapy and endocrine therapy outcomes in young women with stage I HR+/HER2+ breast cancer: An international real-world study
Tal Sella, Frederieke van Duijnhoven, Hans Wildiers, et al.
Nature Communications
|
September 20, 2022
Single cell atlas identifies lipid-processing and immunomodulatory endothelial cells in healthy and malignant breast
Vincent Geldhof, Laura P M H de Rooij, Liliana Sokol, et al.
The New England Journal of Medicine
|
December 11, 2024
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer
Komal L Jhaveri, Patrick Neven, Monica Lis Casalnuovo, et al.
Page
of 39